GLPG1690

CAS: 1628260-79-6

Ref. TR-G411813

Produktinformation

• Name: GLPG1690
• Synonyme: 2-[[2-ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]-methylamino]-4-(4-fluorophenyl)-1,3-thiazole-5-carbonitrile

Beschreibung

Applications GLPG1690 is a selective autotaxin inhibitor discovered by Galapagos, with potential application in idiopathic pulmonary disease (IPF). In a Phase 1 study in healthy human volunteers, GLPG1690 demonstrated favorable safety and tolerability, as well as a strong pharmacodynamic signal implying target engagement.
References Desroy, Nicolas., et al.:J Med Chem., 60, 3580 (2017); Nikolaou, Aikaterini., et al.: J Med Chem., 61, 3697 (2018); Kuttruff, Christian A., et al.: ACS Med Chem Lett., 8, 1252 (2017)

• Marke: TRC

Chemische Eigenschaften

• Molekulargewicht: 588.699
• Formel: C₃₀H₃₃FN₈O₂S
• Farbe/Form: Neat
• InChl: InChI=1S/C30H33FN8O2S/c1-4-24-29(35(3)30-34-27(25(14-32)42-30)20-5-7-21(31)8-6-20)39-15-22(13-19(2)28(39)33-24)37-11-9-36(10-12-37)18-26(41)38-16-23(40)17-38/h5-8,13,15,23,40H,4,9-12,16-18H2,1-3H3
• InChI Key: InChIKey=QGZKDVFQNNGYKY-UHFFFAOYSA-N
• SMILES: CCc1nc2c(C)cc(N3CCN(CC(=O)N4CC(O)C4)CC3)cn2c1N(C)c1nc(-c2ccc(F)cc2)c(C#N)s1